Jacques De Greve

Summary

Affiliation: Universitair Ziekenhuis Brussel
Country: Belgium

Publications

  1. pmc miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells
    Gang Chen
    Department of Pathology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, People s Republic of China
    PLoS ONE 8:e60317. 2013
  2. pmc Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib
    Gang Chen
    Department of Pathology, First Affiliated Hospital, Guangxi Medical University, Nanning Guangxi, People s Republic of China
    PLoS ONE 8:e59708. 2013
  3. doi request reprint Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
    J de Greve
    Oncologisch Centrum UZ Brussel, Brussels, Belgium
    Lung Cancer 76:123-7. 2012
  4. pmc Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells
    Gang Chen
    Laboratory of Molecular Oncology and Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
    Biol Proced Online 13:1. 2011
  5. pmc Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families
    Mateja Krajc
    Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia
    BMC Med Genet 9:83. 2008
  6. pmc The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
    Vida Stegel
    Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia
    BMC Med Genet 12:9. 2011
  7. doi request reprint [Targeted therapies in the treatment of non-small cell lung cancer]
    Jacques De Greve
    Dienst Medische Oncologie, Oncologisch Centrum, UZ Brussel VUB Laarbeeklaan 101, B 1090 Jette, Belgique
    Bull Cancer 95:358-64. 2008
  8. doi request reprint Hereditary breast cancer: from bench to bedside
    Jacques De Greve
    Medical Oncology, Laboratory of Molecular Oncology, Familial Cancer Clinic, UZ Brussel, Laarbeeklaan, Jette, Belgium
    Curr Opin Oncol 20:605-13. 2008
  9. ncbi request reprint Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases
    Bart Neyns
    Medical Oncology, UZ Brussel, Brussels, Belgium
    Anticancer Res 28:2459-67. 2008
  10. doi request reprint Performance of two geriatric screening tools in older patients with cancer
    Cindy Kenis
    Cindy Kenis, Koen Milisen, Johan Flamaing, and Hans Wildiers, University Hospitals Leuven Koen Milisen, Johan Flamaing, and Hans Wildiers, Katholieke Universiteit Leuven Lore Decoster, Katrien Van Puyvelde, Jacques De Grève, and Godelieve Conings, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels and Jean Pierre Lobelle, Consultant in Statistics, Beernem, Belgium
    J Clin Oncol 32:19-26. 2014

Collaborators

Detail Information

Publications34

  1. pmc miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells
    Gang Chen
    Department of Pathology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, People s Republic of China
    PLoS ONE 8:e60317. 2013
    ..6 weeks in miR-146a high patients vs. 4.8 weeks in miR-146a low patients, P<0.05). miR-146a is therefore a strong candidate prognostic biomarker in NSCLC. Thus inducing miR-146a might be a therapeutic strategy for NSCLC...
  2. pmc Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib
    Gang Chen
    Department of Pathology, First Affiliated Hospital, Guangxi Medical University, Nanning Guangxi, People s Republic of China
    PLoS ONE 8:e59708. 2013
    ....
  3. doi request reprint Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
    J de Greve
    Oncologisch Centrum UZ Brussel, Brussels, Belgium
    Lung Cancer 76:123-7. 2012
    ..These findings suggest that afatinib is a potential novel treatment option for this subgroup of patients, even when other EGFR and HER2 targeting treatments have failed...
  4. pmc Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells
    Gang Chen
    Laboratory of Molecular Oncology and Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
    Biol Proced Online 13:1. 2011
    ..The knockdown of the epidermal growth factor receptor (EGFR) gene with eight individual EGFR small interfering RNAs (siRNAs) was estimated by RT-qPCR using three different RT-qPCR primer sets...
  5. pmc Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families
    Mateja Krajc
    Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia
    BMC Med Genet 9:83. 2008
    ..A second objective was to determine the cancer phenotype of these families...
  6. pmc The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
    Vida Stegel
    Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia
    BMC Med Genet 12:9. 2011
    ..the BRCA1 and BRCA2 mutation spectrum and mutation detection rates according to different family histories were investigated in 521 subjects from 322 unrelated Slovenian cancer families with breast and/or ovarian cancer...
  7. doi request reprint [Targeted therapies in the treatment of non-small cell lung cancer]
    Jacques De Greve
    Dienst Medische Oncologie, Oncologisch Centrum, UZ Brussel VUB Laarbeeklaan 101, B 1090 Jette, Belgique
    Bull Cancer 95:358-64. 2008
    ..Specific mechanisms of resistance for these agents are gradually discovered and the new drugs being able to overcome these resistances are at the horizon...
  8. doi request reprint Hereditary breast cancer: from bench to bedside
    Jacques De Greve
    Medical Oncology, Laboratory of Molecular Oncology, Familial Cancer Clinic, UZ Brussel, Laarbeeklaan, Jette, Belgium
    Curr Opin Oncol 20:605-13. 2008
    ..A number of recent findings with regard to hereditary breast cancer should affect the criteria and scope of routine genetic testing and, soon, breast cancer therapy...
  9. ncbi request reprint Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases
    Bart Neyns
    Medical Oncology, UZ Brussel, Brussels, Belgium
    Anticancer Res 28:2459-67. 2008
    ..Both hepatic arterial infusion (HAI) of chemotherapy and cetuximab (CET) have interesting activity for the treatment of colorectal cancer liver metastases (CRC-LM)...
  10. doi request reprint Performance of two geriatric screening tools in older patients with cancer
    Cindy Kenis
    Cindy Kenis, Koen Milisen, Johan Flamaing, and Hans Wildiers, University Hospitals Leuven Koen Milisen, Johan Flamaing, and Hans Wildiers, Katholieke Universiteit Leuven Lore Decoster, Katrien Van Puyvelde, Jacques De Grève, and Godelieve Conings, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels and Jean Pierre Lobelle, Consultant in Statistics, Beernem, Belgium
    J Clin Oncol 32:19-26. 2014
    ....
  11. doi request reprint Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families
    Sylvia De Brakeleer
    Laboratory of Molecular Oncology, Vrije Universiteit Brussel, 1090 Brussels, Belgium
    Hum Mutat 31:E1175-85. 2010
    ..In conclusion, we provide evidence for an increased breast cancer risk associated to specific BARD1 germline mutations. However, these BARD1 mutations occur in a minority of hereditary breast cancer families...
  12. doi request reprint Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy
    Samuel Bral
    Department of Radiation Oncology, Oncology Center, Brussels University Hospital, Brussels, Belgium
    Cancer 116:241-50. 2010
    ....
  13. pmc Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
    Gang Chen
    Laboratory of Medical and Molecular Oncology and Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium
    BMC Med 10:28. 2012
    ....
  14. doi request reprint Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab
    Shasha Lv
    Laboratory of Molecular Oncology and Department of Medical Oncology, University Hospital Brussels, Free University Brussels, 1090 Brussels, Belgium
    Int J Oncol 41:1029-35. 2012
    ..Prospective investigation of both the EGFR amplification and mutation status in clinical trials with EGFR-targeted therapies for GB is indicated...
  15. doi request reprint Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC)
    Denis Schallier
    Department of Medical Oncology, UZ Brussel, Brussels, Belgium
    J Thorac Oncol 4:728-35. 2009
    ..We report the long term and overall results of a triplet induction chemotherapy regimen followed by standard radiotherapy in patients with locally advanced inoperable stage III non-small cell lung cancer...
  16. doi request reprint Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction
    Gang Chen
    Laboratory of Molecular Oncology and Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
    Anal Biochem 398:266-8. 2010
    ..The RT-qPCR assay using transcript-specific primers can detect as few as 1% T790M transcripts in a wt background and, therefore, will be useful in RNA interference studies specifically targeting mutant RNA...
  17. ncbi request reprint Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers
    Sylvia De Brakeleer
    Laboratory of Molecular Oncology, Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
    Mutat Res 619:104-12. 2007
    ....
  18. ncbi request reprint Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents
    Gang Chen
    Laboratory of Medical and Molecular Oncology, Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    Biochem Biophys Res Commun 431:623-9. 2013
    ..The combination of a potent, irreversible kinase inhibitor such as afatinib, with T790M-specific-siRNAs should be further investigated as a new strategy in the treatment of lung cancer containing the resistant T790M mutation...
  19. pmc Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
    Joanna Vermeij
    Laboratory for Molecular Oncology, Universitair Ziekenhuis, Vrije Universiteit Brussel, 1090 Brussels, Belgium
    BMC Cancer 8:3. 2008
    ..The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. An integrated analysis of both genes could help define the proportion of patients that would potentially benefit from targeted therapies...
  20. doi request reprint Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings--preliminary results
    Smitha Makkat
    Department of Radiology, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    Radiology 249:471-82. 2008
    ..To prospectively determine whether breast carcinomas possess characteristic values of tumor blood flow (TBF) that correlate with pathologic and molecular prognostic markers...
  21. ncbi request reprint De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes
    Erik Teugels
    Laboratory of Molecular and Medical Oncology, AZ VUB, Vrije Universiteit Brussel, Laarbeeklaan 101, B1090 Brussels, Belgium
    Hum Mutat 26:284. 2005
    ....
  22. ncbi request reprint Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma
    Shasha Lv
    Laboratory of Molecular Oncology and Department of Medical Oncology, Oncology Center, UZ Brussels, University Hospital Brussels, Free University Brussels, Brussels, Belgium
    Anticancer Res 31:4457-63. 2011
    ..Our observations support the hypothesis that IDH1 mutation may correlate with the benefit from VEGF(R)- versus EGFR-targeted therapy at the time of recurrence in glioma patients...
  23. doi request reprint Systematic detection of pathogenic alu element insertions in NGS-based diagnostic screens: the BRCA1/BRCA2 example
    Sylvia De Brakeleer
    Laboratory of Molecular and Medical Oncology, Vrije Universiteit Brussel, Belgium
    Hum Mutat 34:785-91. 2013
    ..1739_1740insAlu in BRCA1 and c.156_157insAlu in BRCA2...
  24. ncbi request reprint The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Eur J Cancer 44:84-91. 2008
    ..To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after > or = 4 months on letrozole alone...
  25. ncbi request reprint Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study
    Filomena Mazzeo
    University Hospital St Luc, Brussels, Belgium
    Anticancer Res 31:1407-9. 2011
    ..To determine imatinib nonadherence rates in patients with gastrointestinal tumors (GIST) over 90 days...
  26. doi request reprint The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients
    Marijke de Couck
    Faculty of Medicine and Pharmacy, Free University of Brussels VUB, Brussels, Belgium
    Oncol Rep 30:2435-41. 2013
    ..Together with recent experimental findings, these results propose a modulatory role of vagal nerve activity in cancer. Therefore, routine measurement of HRV in estimating prognosis in cancer may be considered. ..
  27. doi request reprint The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer
    Lore Decoster
    Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium Electronic address
    J Geriatr Oncol 4:235-41. 2013
    ..The aim of this prospective study in older patients with cancer was to evaluate how clinical assessment (including age) determines the physician's treatment decisions, and how geriatric assessment (GA) further influences these decisions...
  28. doi request reprint Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)
    Felipe Ades
    Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Belgium
    J Chemother 25:239-46. 2013
    ..We concluded that in patients with newly diagnosed metastatic tumours, CupPrint has low accuracy in diagnosing the primary cancer site. ..
  29. doi request reprint Savene® (dexrazoxane) use in clinical practice
    Christel Fontaine
    Department of Medical Oncology, University Hospital of Brussels, 1090, Jette, Belgium
    Support Care Cancer 20:1109-12. 2012
    ..Adverse events, mainly haematological toxicity, were rapidly reversible. The objective of the study was to assess, in clinical practice, the efficacy and safety profile of Savene® for ACEV in different Belgian hospitals...
  30. ncbi request reprint Phase II study of preoperative helical tomotherapy for rectal cancer
    Mark de Ridder
    Department of Radiation Oncology, Oncologisch Centrum UZ Brussel, Brussels, Belgium
    Int J Radiat Oncol Biol Phys 70:728-34. 2008
    ..To explore the efficacy and toxicity profile of helical tomotherapy in the preoperative treatment of patients with rectal cancer...
  31. ncbi request reprint Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases
    Bart Neyns
    Department of Medical Oncology, Oncologisch Centrum AZ VUB, Brussels, Belgium
    Anticancer Res 26:611-9. 2006
    ..Despite the progress made in the treatment of metastatic colorectal cancer (CRC), the results of second-line chemotherapy remain poor...
  32. doi request reprint Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy
    Mina Leyder
    Service of Prenatal Medicine, UZ Brussel, Brussels, Belgium
    Gynecol Obstet Invest 71:141-4. 2011
    ....
  33. doi request reprint Individual cancer risk as a function of current age and risk profile
    M C M Goossens
    Free University Brussels VUB, Brussels, Belgium
    Eur J Cancer Prev 19:485-95. 2010
    ..Current smokers can now be given absolute risk reduction estimates of smoking cessation. To keep the life table risk estimates up to date, they must be repeated every couple of years, using up-to-date incidence and mortality data...
  34. ncbi request reprint Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity
    Ziad Zeinoun
    Laboratory of Medical and Molecular Oncology, Oncologisch Centrum, AZ VUB, Laarbeeklaan 101, B 1090, Jette, Belgium
    Cancer Detect Prev 27:380-8. 2003
    ..As disruption of TGF-beta's autocrine growth circuit is thought to be an early event in the malignant transformation of several epithelial cancers, early correction of this defect might in the future lead to cancer preventive strategies...